We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Assay Targets Antibiotic Resistance with Pathogen Identification

By LabMedica International staff writers
Posted on 18 Feb 2019
A rapid diagnostic device has been developed to detect and identify the source of an infection in less than one hour. More...
The proprietary DNA-based technology has the potential to revolutionize infection control by providing a POC, inexpensive, rapid diagnosis of pathogens in humans, animals and agriculture.

The C-AST assay is being developed in tandem with the CAPTURE pathogen identification assay, which stands for confirm active pathogens through an amplified RNA expression platform. The CAPTURE assay identifies bacterial or fungal pathogens' RNA in liquid samples, including blood, urine, saliva, and other types, with a "universal fluorescent marker," applying the firm's proprietary array using a machine-learning algorithm.

Earlier this month, GeneCapture scientists presented data collected from the functioning prototype system for its collaborators at the University of Alabama (Huntsville, AL, USA). They tested four antibiotics: ampicillin (AMP), amoxicillin/clavulanate (AMC), trimethoprim/sulfamethoxazole (SXT), and ciprofloxacin (CIP), against the nine pathogens responsible for most UTI cases. The group organisms include strains of species like Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus aureus.

The scientists initially evaluated 70 runs comparing 181 drug exposures to no-drug controls. They then evaluated 25 subsequent assays against culture results, focusing on AMP, AMC, SXT, and CIP, with most being tested in duplicate or triplicate. The group did not encounter false resistances or false sensitivities using the drugs. They also emphasized that the C-AST assay performed identically to culture results but in a much shorter period of time. The C-AST assay can test the effectiveness of various antibiotics against pathogens in between 5 and 75 minutes.

Peggy L. Sammon, co-founder and the CEO of GeneCapture, said, “We realized that for most infections, knowing the identity of the organism wasn't enough, so we developed the C-AST assay to give us information about the right drugs to use once CAPTURE has identified an organism. Knowing the type of organism and its concentration allows the C-AST assay to quickly analyze which antibiotics are sensitive or resistant."

Related Links:
University of Alabama


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.